Un ensayo clínico presentado en ASCO reportó una mejora significativa en la supervivencia de pacientes con adenocarcinoma ductal pancreático.

Daraxonrasib has been hailed as ‘landscape-changing’ for people with the disease

Experts hail daraxonrasib as ‘gamechanger’ for patients with advanced pancreatic cancer

Doctors today hailed a breakthrough in the fight against pancreatic cancer after a new drug was shown to give patients precious extra months of life.

Un fármaco innovador consigue supervivencias de hasta 13 meses, el doble que con la quimioterapia convencional. Es una mejora sin precedentes en décadas

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or…

Leggi su Sky TG24 l'articolo Tumore al pancreas, un nuovo farmaco sperimentale aumenta la sopravvivenza. Lo studio

New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer.

The drug is called daraxonrasib and it blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases — a target that had eluded treatment for…

Los pacientes tratados alcanzan una supervivencia media de 13,2 meses frente a los 6,7 de la quimioterapia convencional. En la investigación ha participado el Hospital Clínic de…

Un nuovo studio clinico sta attirando grande attenzione nella comunità scientifica internazionale per i risultati ottenuti nel trattamento del tumore al

Il farmaco daraxonrasib contro il cancro al pancreas ha dimostrato risultati rivoluzionari in un nuovo studio

A groundbreaking daily pill has been shown to double survival time for patients battling the world's deadliest cancer, marking a major advancement in medical research.

S-a descoperit că o pastilă poate aproape dubla perioada de supraviețuire pentru pacienții cu cancer pancreatic avansat, experții descriind studiul clinic ca fiind revoluționar.

La molecola daraxonrasib raddoppia la sopravvivenza contro il tumore al pancreas: i dati promettenti dello studio clinico presentati all'Asco

Los resultados del ensayo clínico con daraxonrasib se presentaron ayer en la reunión anual de la Sociedad Estadounidense de Oncología Clínica en Chicago. “Representa un cambio de…

The drug daraxonrasib nearly doubled the overall survival rates of pancreatic cancer patients. Here's how it works and who can get it.

People with advanced pancreatic cancer taking an experimental daily pill lived nearly twice as long as those receiving chemotherapy infusions

The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.

Uno studio ha dimostrato che una nuova pillola ha contribuito a raddoppiare il tempo di sopravvivenza dei pazienti affetti da una forma avanzata e aggressiva di cancro al…

Un ensayo clínico presentado en ASCO reportó una mejora significativa en la supervivencia de pacientes con adenocarcinoma ductal pancreático.